Genentech’s Ocrevus data show NfL may be a biomarker for predicting future disability outcomes
– Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in
Read more– Blood neurofilament light chain (NfL) levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in
Read moreSynlogic in clinical collaboration with Roche to explore Synlogic’s Synthetic Biotic medicine for advanced solid tumors
Read moreRoche presents data from a mock clinical trial study suggesting that next-generation discovery proteomics is ready for use in clinical
Read moreRoche said Monday it got accelerated approval to Tecentriq plus chemotherapy for the treatment of adults with unresectable triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test.
Read moreRoche will fully buy Spark Therapeutics at a price of $114.50 per share in an all-cash transaction, or for $4.3
Read moreRoche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
Read moreRoche will wait until September 2019 for the FDA’s decision, before it can combine Tecentriq with Abraxane and carboplatin for the first-line treatment of lung cancer patients, who don’t have EGFR or ALK genomic tumour aberrations.
Read moreBioPorto and Roche agreed that BioPorto will deliver a neutrophil gelatinase-associated lipocalin (NGAL) test for use on Roche’s cobas c
Read moreBoehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and development of orally available novel Locked
Read moreHorizon Discovery Group has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays.
Read more